Timeline

Voting rights breakdown

Declared beneficial owners · 23

A single, collectively filed disclosure: the voting-rights rate applies to the whole group, not to each person.

• Aravis Venture I LP40.1%
• Astellas Venture Capital, LLC40.1%
• Auriga Ventures III40.1%
• Baltisches Haus Limited40.1%
• BioMedInvest II LP40.1%
• Dansk Innovationsinvestering P/S c/o Maj Invest A/S40.1%
• Entrepreneurs Fund General Partners Limited40.1%
• Evolva Holding SA40.1%
• Mona Lisa Capital SA40.1%
• Novartis Bioventures Ltd40.1%
• Renaisance PME fondation suisse d investissement / Mona Lisa40.1%
• Sunstone Life Science Ventures Fund I K/S40.1%
• Symbion Capital I A/S40.1%
• Wellington Partners Ventures III Life Science Fund L.P40.1%
• Wellington Partners Ventures III Life Science Network Fund L40.1%
• Neil Goldsmith40.1%
• Alexandra SantAna Sørensen40.1%
• Pascal Longchamp40.1%
• Jakob Dynnes Hansen40.1%
• Jutta Heim40.1%
• PM Murali40.1%
• Ventureast Trustee Company P Limited40.1%
• APIDC Venture Capital P Limited40.1%

Notice details

Beneficial owner

Aravis Venture I LP

On December 13, 2010 the members of the group (the Lock-up Group) have agreed to partially extend the lock-up undertaking entered into prior to the merger between Arpida Ltd. (now Evolva Holding SA) with Evolva SA with regard to a part of their shares in Evolva Holding SA (the Shares) and conversion rights (as previously disclosed). With regard to 45% of their initial aggregate holdings (i.e., with regard to 51,011,141 Shares and 4,949,046 conversion rights) the lock-up undertaking continues to be in force up to and including August 31, 2011, provided however that shares may be transferred from this Lock-up Group into the coordinated sale group under certain conditions. Any such transfers would be disclosed. With regard to 45% of their initial aggregate holdings (i.e., with regard to 51,011,142 Shares and 4,949,046 conversion rights) the lock-up extension agreed on December 13, 2010 has expired on May 23, 2011; Additional information can be downloaded from the Evolva website www.evolva.com/press-investors/investors/disclosure-shareholdings